Clinical Trial Update: DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 [Phase 4]

View source ↗

Summary

Phase 4 trial studying dapagliflozin plus exenatide on central regulation of appetite in type 2 diabetes and obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Type 2 Diabetes Mellitus, Obesity | Phase 4 | Status: COMPLETED